Brief: Nkarta Announces FDA Agreement On Outpatient Dosing Of Nkx019 In Autoimmune Disease, Expanding Access To Community Rheumatology Centers

Nkarta

15/04/2026 22:21

April 15 (Reuters) - Nkarta Inc NKTX.O:

NKARTA ANNOUNCES FDA AGREEMENT ON OUTPATIENT DOSING OF NKX019 IN AUTOIMMUNE DISEASE, EXPANDING ACCESS TO COMMUNITY RHEUMATOLOGY CENTERS

NKARTA INC - FDA AGREES TO OUTPATIENT ADMINISTRATION OF NKX019 IN COMMUNITY SETTINGS

NKARTA INC - FDA AGREES TO REDOSING OPTION IN NTRUST-1 AND NTRUST-2 STUDIES

NKARTA INC - DOSING CONTINUES AT 4 BILLION CELLS PER DOSE, DATA EXPECTED THIS YEAR

NKARTA INC - GEOGRAPHIC MONITORING REQUIREMENTS REMOVED FOR NTRUST-1 AND NTRUST-2

NKARTA INC - RHEUMATOID ARTHRITIS COHORT TO BE ADDED TO NTRUST-2 STUDY

Source text: ID:nGNXbqMP12

Further company coverage: NKTX.O

 ((Reuters.Briefs@thomsonreuters.com;))